FDA Brief

Warning letters Drugs

FDA warning letter to

Mr. Lulu LLC

High riskIssued Jun 1, 2023Posted Jun 6, 2023Division of Pharmaceutical Quality Operations IV

FDA warned Mr. Lulu LLC of Claremont, California, that its OTC sunscreen drops were adulterated: no release testing, no identity testing, no batch records.

What happened

FDA inspected Mr. Lulu LLC's drug manufacturing facility at 815 West 10th Street, Claremont, California, from November 30 to December 9, 2022. Investigators found the firm shipped multiple batches of Mr. Lulu Sunscreen Drops SPF32 to the U.S. market without testing them for zinc oxide and titanium dioxide content, without testing incoming ingredients for identity, and without written batch records for batches made in March 2022 and November 2022. FDA called the firm's December 13, 2022 response to the inspection form (Form FDA 483, the list of observations from the inspection) inadequate, and said the product is adulterated, meaning it fails FDA's legal requirements.

What FDA found

  1. The firm released batches of sunscreen without laboratory testing to confirm the identity and strength of the active ingredients, checking only scent, appearance and texture, and not writing the results down.

    21 CFR 211.165(a)
  2. The firm did not test each incoming ingredient lot to confirm what it was, had no written supplier qualification procedure, and relied on supplier certificates of analysis without validating them.

    21 CFR 211.84(d)(1) and (2)
  3. The firm used food-grade titanium dioxide as a drug ingredient without ensuring it met the United States Pharmacopeia (USP) standard, the official public quality standard for drugs.

    Section 501(b) of the FD&C Act
  4. The firm never validated its manufacturing process, never qualified its equipment, and never validated cleaning, and it admitted the mixer used to make the sunscreen is also used for personal use in the owner's kitchen.

    21 CFR 211.100(a)
  5. The firm had no executed batch production records for the sunscreen batches it made and released.

    21 CFR 211.188
  6. The firm had no quality control unit and no written procedures for deviations, complaints, recalls or stability, and it assigned no batch numbers, so finished product cannot be traced.

    21 CFR 211.22

What FDA wants

FDA tells the firm to reply in writing within 15 working days describing corrections and how it will prevent recurrence, and to say whether it plans to resume making drugs at the facility before doing so. If it cannot finish within 15 working days, it must explain the delay and give a completion schedule.

Who should pay attention

  • retailers and distributors that sold or stocked Mr. Lulu sunscreen drops
  • small cosmetics and drug makers using shared or kitchen equipment
  • brands that accept supplier certificates of analysis instead of testing incoming ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk